KPHMWKiora Pharmaceuticals, Inc.

About Kiora Pharmaceuticals, Inc. (KPHMW)

Kiora Pharmaceuticals, Inc. (KPHMW) is a N/A company headquartered in Encinitas, CA, United States whose shares trade over-the-counter on the Pink tier.

Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 2 clinical trials indicated for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. The company is also developing KIO-104, a non-steroidal, immuno-modulatory, small-molecule inhibitor of dihydroorotate dehydrogenase, currently under phase 1b/2a study for the treatment of posterior non-infectious uveitis, as well as under pre-clinical development for the treatment of proliferative vitreoretinopathy; KIO-101, an eye drop for the treatment of ocular presentation of rheumatoid arthritis; and KIO-201, an eye drop for treating patients undergoing photorefractive keratectomy (PRK) surgery for corneal wound repair. It has commercialization agreement with 4SC Discovery GmbH, for KIO-101; and collaboration agreement with Thea Open Innovation for the development KIO-301.

KPHMW key facts

Ticker symbol

KPHMW

Market tier

Pink

Headquarters

Encinitas, CA, United States

Country of incorporation

US

Year of incorporation

2004

Employees

3

Reporting standard

U.S. Reporting: SEC Reporting

Audit status

Audited

Fiscal year end

12/31

Kiora Pharmaceuticals, Inc. leadership

• Stephen From — CEO, CFO
• Michael Manzo — VP, Eng.

Explore more: Pink stocks · OTC stocks starting with K